Yoav Golan, MD
Infectious Disease · Boston, MANPI 1487760203
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $750,489 of the $1,091,019 with a category attached, or 68.8%. 18 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 31.9% of the total. Reporting peaked in 2019 at $301,359 and has fallen 57.6% since, to $127,800 in 2025. Among infectious disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,073 payments — averaging $1016.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$348K
- AbbVie$307K
- Merck$139K
- Shionogi Inc$79K
- Aimmune Therapeutics, Inc.$79K
- Pfizer$52K
- plus $88K from 12 others
Across 41 payments — averaging $17,248 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tarsus Pharmaceuticals, Inc.$638K
- Janssen Research & Development, LLC$42K
- Merck$26K
- Genentech, Inc.$500
What the payments were for
- Consulting fees$82,5868%
- Speaking & faculty fees$750,48969%
- Travel & lodging$236,47922%
- Food & beverage$20,7792%
- Education$6850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 340 | $347,719 |
| AbbVie(2 entities) | 341 | $306,525 |
| Merck | 147 | $139,013 |
| Shionogi Inc | 56 | $78,762 |
| Aimmune Therapeutics, Inc. | 40 | $78,540 |
| Pfizer(2 entities) | 39 | $52,171 |
| Sanofi Pasteur Inc. | 52 | $52,102 |
| Ferring Pharmaceuticals Inc. | 27 | $21,483 |
| Pfizer S.a.s. | 10 | $3,212 |
| Melinta Therapeutics, LLC | 3 | $3,163 |
| Tetraphase Pharmaceuticals, Inc. | 6 | $3,083 |
| Pfizer Chile S.A. | 1 | $2,000 |
| Cumberland Pharmaceuticals, Inc. | 4 | $1,181 |
| Meitheal Pharmaceuticals, Inc. | 2 | $830 |
| Kowa Research Institute, Inc. | 1 | $575 |
| KOWA Company, LTD. | 1 | $575 |
| Nabriva Therapeutics, PLC | 2 | $54 |
| Biomerieux Inc | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$345,786
- AVYCAZ$250,541
- ZENPEP$77,767
- Fetroja$65,810
- DIFICID$39,046
- ZINPLAVA$39,046
- ZERBAXA$36,990
- FLUZONE HIGH-DOSE$32,040
- PREVNAR 20$26,576
- TEFLARO$20,601
- DALVANCE$18,436
- REBYOTA$18,131
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$17,829
- FLUBLOK QUADRIVALENT$11,900
- PREVYMIS$10,237
- EMBLAVEO$8,730
- NO PRODUCT DISCUSSED$8,042
- PAXLOVID$4,500
- TRUMENBA$4,157
- Xerava$2,917
How this compares
$1,091,019 in reported general payments places this provider in the 95th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 3,609 | $1,096,390 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 2,931 | $616,766 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 1,261 | $82,243 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 251 | $74,268 |
| TwinrixHepatitis A And B Vaccine/Pf | 34 | $4,797 |
| HavrixHepatitis A Virus Vaccine/Pf | 16 | $1,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerAbrysvo | $52,171 | $1,096,3903,609 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 368 infectious disease providers in Massachusetts.
Other infectious disease in Boston
- Nesli BasgozBoston$901K
- Todd EllerinBoston$843K
- Paul SaxBoston$320K
- Davidson HamerBoston$221K
- Camille KottonBoston$195K
- David SnydmanBoston$141K
- Eric RosenbergBoston$134K
- Deborah HungBoston$130K
- Laura KogelmanBoston$54K
- Jay FishmanBoston$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.